Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hookipa Pharma Inc (NQ: HOOK )

3.760 +0.070 (+1.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 60,505
Open 3.700
Bid (Size) 3.600 (10)
Ask (Size) 3.760 (218)
Prev. Close 3.690
Today's Range 3.580 - 3.783
52wk Range 3.414 - 11.30
Shares Outstanding 21,588,756
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
-54.70%
-54.70%
1 Month
-1.57%
-1.57%
3 Month
-20.00%
-20.00%
6 Month
-51.04%
-51.04%
1 Year
-14.53%
-14.53%

More News

Read More
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Why HOOKIPA Pharma (HOOK) Stock Is Volatile Today
Via Benzinga
Deep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views
Via Benzinga
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
HOOKIPA Pharma Announces Board of Directors Changes
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Via InvestorPlace
HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.